Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 4/20 | 0.37 |
| ▸ | PPARG | P37231 | 4/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | SERPINE1 | P05121 | 3/20 | 0.35 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.35 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.35 |
| ▸ | TDP2 | O95551 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.34 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.33 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10257520 | 0.94 | MCL1 (0.37) | MCL1PPARGKMT2ASERPINE1RCE1 | |
| SCHEMBL862343 | 0.93 | MCL1 (0.37) | MCL1PPARGKMT2ASERPINE1RCE1 | |
| SCHEMBL862296 | 0.92 | PPARG (0.41) | MCL1PPARGKMT2ASERPINE1RCE1 | |
| SCHEMBL862488 | 0.90 | SERPINE1 (0.38) | MCL1PPARGKMT2ASERPINE1RCE1 | |
| SCHEMBL10257144 | 0.89 | SERPINE1 (0.38) | MCL1PPARGKMT2ASERPINE1RCE1 | |
| SCHEMBL862192 | 0.89 | PPARG (0.39) | MCL1PPARGKMT2ASERPINE1RCE1 | |
| SCHEMBL862329 | 0.88 | PPARG (0.40) | MCL1PPARGKMT2ASERPINE1CYP2C8 | |
| SCHEMBL862443 | 0.88 | TDP2 (0.36) | PPARGKMT2ACYP2C8TDP2MEN1 | |
| SCHEMBL862708 | 0.88 | CYP2C8 (0.38) | PPARGKMT2ASERPINE1CYP2C8TDP2 | |
| SCHEMBL862454 | 0.88 | CYP2C8 (0.39) | PPARGKMT2ASERPINE1CYP2C8TDP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143305-B2 | 2,3-substituted indole derivatives for treating viral infections | SCHERING CORPORATION (US) | 2012-03-27 | — | — | US | disclosed |
| US-20110033417-A1 | 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | MERCK SHARP & DOHME CORP. | 2011-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110033417-A1 | 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | IDO2, IDO1, IRF3 | MCL1 872/4885PPARG 4093/4885KMT2A 321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.